Kairos Ventures

Vivodyne specializes in developing an automated robotic platform that aims to advance drug discovery and cellular therapies. The company's innovative microfluidic bioengineering technology facilitates the culture of highly realistic human tissue models, allowing researchers to explore complex biological processes. By employing single-cell 4D phenomics and integrating advanced imaging techniques, Vivodyne's system enables the formulation of tailored mixtures of compounds and cell therapies. This comprehensive approach not only accelerates the development of potential cures for various human diseases but also enhances the understanding of human health at a cellular level.

PteroDynamics is dedicated to transforming transportation through the development of sustainable autonomous vertical takeoff and landing (VTOL) aircraft. Established in 2017, the company aims to reduce environmental impact while enhancing mobility. Its innovative Transwing aircraft features a unique wing design that folds during flight, allowing for a seamless transition between rotor-wing and fixed-wing modes. This design optimizes cargo-carrying efficiency, making it suitable for long-range missions across government, military, and commercial sectors. By providing smaller, more stable aircraft capable of carrying heavier payloads with reduced energy consumption, PteroDynamics is at the forefront of the Advanced Air Mobility sector, addressing the growing demand for efficient and eco-friendly transportation solutions.

Behavioral Signals specializes in technology that analyzes human behavior through voice data, focusing on emotion recognition and behavioral analytics. Their primary product, AI-MC, allows enterprises to enhance call center performance by automatically matching customers with the most suitable agents based on voice data and emotional insights. The company utilizes proprietary algorithms to identify core emotions, moods, and interaction patterns, translating these factors into key performance indicators for marketing campaigns. By processing data in real-time, Behavioral Signals enables clients to gain valuable emotional and demographic insights, which can be integrated into various applications and processes to improve overall business outcomes.

TULU is a company based in Tel Aviv, Israel, that specializes in on-demand rentals of household and lifestyle products through its application. The company offers tenants in residential buildings, student housing, and offices access to a wide range of brand-name appliances, grocery staples, and entertainment devices. Utilizing IoT-based smart rental units, TULU customizes its offerings to meet the needs of urban dwellers, while leveraging data to analyze usage patterns and optimize inventory. This approach not only enhances the user experience but also aims to reduce waste and maximize space utilization. TULU operates in 15 cities across the United States and Europe, collaborating with major landlords and top brand manufacturers to provide quality products and services to its customers.

Vivodyne specializes in developing an automated robotic platform that aims to advance drug discovery and cellular therapies. The company's innovative microfluidic bioengineering technology facilitates the culture of highly realistic human tissue models, allowing researchers to explore complex biological processes. By employing single-cell 4D phenomics and integrating advanced imaging techniques, Vivodyne's system enables the formulation of tailored mixtures of compounds and cell therapies. This comprehensive approach not only accelerates the development of potential cures for various human diseases but also enhances the understanding of human health at a cellular level.

AetherTouch specializes in acoustic wave technology that allows users to control electronic devices without direct contact with screens. The company develops a software development kit that facilitates the integration of its technology into various applications and operating systems. By employing advanced signal processing algorithms, AetherTouch's solution offers precise two-dimensional tracking, making it suitable for smartphones, tablets, computers, and larger consumer electronics. This innovative approach aims to reduce power consumption and address privacy concerns commonly associated with conventional camera-based technologies. Additionally, AetherTouch supports scientists in commercializing their technologies, enhancing the potential for advancements in smart device applications.

Novosteo Inc., founded in 2017 and located in West Lafayette, Indiana, focuses on developing and manufacturing innovative drugs aimed at treating bone injuries and diseases. The company addresses significant health issues related to bone fractures, including morbidity, mortality, and reduced mobility and productivity. Its scientific co-founders from Purdue University have pioneered a proprietary chemistry approach that targets bone regeneration. Novosteo's drug discovery platform features a range of fracture-targeted therapeutics designed to deliver healing agents directly to fracture sites, enhancing the healing process and alleviating the debilitating effects associated with bone injuries. Through its novel biologics, Novosteo aims to improve patient outcomes and quality of life.

Provivi Inc. specializes in developing biopesticides aimed at pest management in agriculture, commercial sectors, households, and public health. The company's innovative approach focuses on using insect pheromones, which provide a safe, environmentally friendly alternative to traditional pesticides. By leveraging biocatalysis technology initially developed at the California Institute of Technology, Provivi enhances the synthesis of these biopesticides, ensuring they are effective and free from toxic residues. Founded in 2013 and based in Santa Monica, California, the company collaborates with distributors worldwide to deliver its products, which are designed to protect food supplies sustainably and affordably. With a team of experienced professionals from biotechnology and the agricultural chemicals industry, Provivi is positioned to transform pest management practices through its advanced biological processes.

Anycart is a meal discovery and grocery shopping platform based in Mountain View, California. It allows users to search for meals they want to cook and provides relevant recipes, automatically adding the necessary ingredients to a preferred grocery delivery service cart. The platform features step-by-step video cooking instructions, making meal preparation straightforward and accessible. Additionally, Anycart suggests alternative recipes that can utilize leftover ingredients, enhancing efficiency in meal planning. Originally established in 2019 during the Amazon Alexa Accelerator in Seattle, the company aims to simplify the grocery shopping experience and promote homemade cooking.

Foldax, Inc. is a company based in Salt Lake City, Utah, that specializes in the design and manufacture of synthetic heart valves for patients with aortic, mitral, or tricuspid valve disease. Founded in 2013, Foldax focuses on developing innovative heart valves made from a unique biopolymer technology that aims to provide non-thrombogenic solutions at significantly lower costs compared to traditional artificial or tissue valves. Their valves can be delivered through both transcatheter and surgical methods, offering a potential treatment option that may reduce or eliminate the need for long-term anticoagulant medications, thereby minimizing associated risks and side effects.

Specter Aerospace specializes in developing hypersonic vehicles that enhance combustion processes for energy, aerospace, and national security applications. The company employs innovative plasma-assisted combustion techniques, utilizing a proprietary fuel nozzle design to optimize combustion reactions. This technology aims to address complex combustion challenges, resulting in significant improvements in fuel efficiency, emissions reduction, and operational safety. By integrating advanced technologies, Specter Aerospace enables its clients to expand the capabilities of modern engines, ultimately contributing to more sustainable and efficient aerospace solutions.

Turbodega S.A.C. is a technology company based in Lima, Peru, that specializes in developing a mobile application platform aimed at modernizing the supply chain for small grocery stores, known as bodegas. Established in 2018, the platform utilizes artificial intelligence to automate order processes, optimize inventory management, and provide real-time tracking of daily sales. By digitizing the traditional supply chain, Turbodega enables small retailers to streamline operations and enhance their competitiveness against larger grocery chains, ultimately helping them increase revenue and improve efficiency.

Actinia specializes in developing advanced technology for the detection of hard radiation, specifically gamma rays and X-rays. The company utilizes a unique perovskite-based material that offers superior sensitivity to X-rays and enhanced energy resolution for gamma rays. This innovative approach positions Actinia to serve various industries, including nuclear energy, non-proliferation, and medical imaging, by providing high-performance detector technologies tailored to their specific needs.

PteroDynamics is dedicated to transforming transportation through the development of sustainable autonomous vertical takeoff and landing (VTOL) aircraft. Established in 2017, the company aims to reduce environmental impact while enhancing mobility. Its innovative Transwing aircraft features a unique wing design that folds during flight, allowing for a seamless transition between rotor-wing and fixed-wing modes. This design optimizes cargo-carrying efficiency, making it suitable for long-range missions across government, military, and commercial sectors. By providing smaller, more stable aircraft capable of carrying heavier payloads with reduced energy consumption, PteroDynamics is at the forefront of the Advanced Air Mobility sector, addressing the growing demand for efficient and eco-friendly transportation solutions.

Pinpoint Therapeutics is a preclinical stage company focused on developing innovative cancer treatment options that specifically inhibit autophagy, a critical pathway associated with cell survival and resistance to treatment. The company's research centers on a newly identified enzyme known as PPT1, which is prevalent in various cancer types. By targeting this enzyme, Pinpoint aims to create inhibitors that can be used alone or in combination with other therapies to help patients overcome resistance to existing cancer treatments.

GuRu Wireless, Inc. enables safe, effective and customizable transmission of power over-the-air using proprietary millimeter-wave (mmWave) integrated circuits, modules and proprietary Smart RF Lensing technology. A miniature-sized power transfer system delivers power at an unprecedented distance efficiently and with precision. GuRu's wireless solution can be used as a charging hub or a power source in many settings where access to an energy source is needed. It is easy to install, safe, and sophisticated enough to find and adjust for various power levels to sync with the needs of any device. Even during use, it continuously charges devices and as a safety measure, reroutes power as necessary. Founded in 2017 by a team of scientists and engineers from Caltech, GuRu aims to ensure access to power be as ubiquitous as WiFi.

Actuate Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Fort Worth, Texas, with an additional office in Dublin, Ireland. The company focuses on developing novel therapeutics that target Glycogen Synthase Kinase-3β (GSK-3β) for the treatment of various conditions, including Alzheimer’s disease, bipolar disorder, type II diabetes, inflammatory diseases, and several high-impact cancers such as glioblastoma, ovarian, breast, and pancreatic cancers. Actuate is advancing its lead compound, elraglusib (formerly known as 9-ING-41), which is designed to inhibit GSK-3β and disrupt cancer cell survival and growth. The company has demonstrated promising anti-tumor activity in preclinical models, particularly for difficult-to-treat cancers. Actuate Therapeutics aims to discover, develop, and commercialize new therapeutic agents that address significant unmet medical needs in oncology and neurodegeneration.

MixComm Inc. is a fabless semiconductor company based in Chatham, New Jersey, specializing in the development of wireless technology solutions for a variety of applications. Founded in 2017, the company focuses on creating advanced millimeter-wave products using RFSOI process technology. These products are designed to enhance performance and integration for 5G infrastructure and satellite communication. MixComm's offerings cater to numerous electronic devices, including smartphones, laptops, Wi-Fi routers, smart TVs, game consoles, virtual-reality headsets, and radar systems used in vehicles and defense electronics. By providing application-specific chips, MixComm aims to support the evolving needs of the wireless communications market.

Provivi Inc. specializes in developing biopesticides aimed at pest management in agriculture, commercial sectors, households, and public health. The company's innovative approach focuses on using insect pheromones, which provide a safe, environmentally friendly alternative to traditional pesticides. By leveraging biocatalysis technology initially developed at the California Institute of Technology, Provivi enhances the synthesis of these biopesticides, ensuring they are effective and free from toxic residues. Founded in 2013 and based in Santa Monica, California, the company collaborates with distributors worldwide to deliver its products, which are designed to protect food supplies sustainably and affordably. With a team of experienced professionals from biotechnology and the agricultural chemicals industry, Provivi is positioned to transform pest management practices through its advanced biological processes.

Linnaeus Therapeutics, Inc. is a biotechnology company based in Haddonfield, New Jersey, focused on the identification and development of small molecule agents for the treatment of cancer and skin pigmentation disorders. Founded in 2016, the company builds on research from the Ridky lab at the University of Pennsylvania. Linnaeus's therapeutics are designed to modulate cellular differentiation, allowing for the precise regulation of melanin production in skin cells. This approach aims to provide effective treatments for conditions associated with oncogenic mutations, thereby addressing both cancer and disorders related to pigmentation.

New Age Meats is a biotechnology company based in San Francisco, California, founded in 2017. The company specializes in producing cultivated meat using an automated, data-driven platform and advanced stem cell technology. By growing meat from animal cells rather than relying on traditional animal slaughter, New Age Meats aims to create healthier and more sustainable meat alternatives.

Kencko is dedicated to making organic fruits and vegetables accessible in convenient forms that fit seamlessly into daily routines. The company specializes in producing instant smoothies that allow consumers to effortlessly incorporate organic produce into their breakfast. These smoothies are free from added sugars, chemicals, and colorants, ensuring that all nutritional content is preserved. By providing hassle-free options for healthy consumption, Kencko aims to transform the way individuals enjoy fresh produce, making nutritious choices easier and more appealing.

Actuate Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Fort Worth, Texas, with an additional office in Dublin, Ireland. The company focuses on developing novel therapeutics that target Glycogen Synthase Kinase-3β (GSK-3β) for the treatment of various conditions, including Alzheimer’s disease, bipolar disorder, type II diabetes, inflammatory diseases, and several high-impact cancers such as glioblastoma, ovarian, breast, and pancreatic cancers. Actuate is advancing its lead compound, elraglusib (formerly known as 9-ING-41), which is designed to inhibit GSK-3β and disrupt cancer cell survival and growth. The company has demonstrated promising anti-tumor activity in preclinical models, particularly for difficult-to-treat cancers. Actuate Therapeutics aims to discover, develop, and commercialize new therapeutic agents that address significant unmet medical needs in oncology and neurodegeneration.

Xidas is a technology company focused on creating advanced micro-scale solutions tailored for various sectors, including IoT, industrial applications, and life technology. Utilizing a proprietary miniaturization approach known as Amalga, Xidas combines innovative manufacturing techniques, design methodologies, and diverse materials to produce products that meet previously unattainable specifications. The company specializes in developing semiconductors, sensors, and 3D micro-devices, employing non-silicon manufacturing processes to deliver microelectronics substrates, micro-actuators, and printed circuit boards. Xidas aims to serve its industrial clients by offering industry-first technologies and highly integrated smart modules and sensors, facilitating their implementation in a wide range of IoT scenarios and enhancing capabilities in biotech and medical device applications.

Transient Plasma Systems, Inc. specializes in the development and manufacture of pulsed power systems for various research and commercial applications. Founded in 2009 and based in Torrance, California, the company produces pulse generators and nanosecond pulsed power systems that facilitate voltage and current measurement. Its innovative technology utilizes ultra-fast, high-voltage electrical pulses to create energetic electrons throughout a volume, rather than focusing them at a single point, which results in a more efficient ignition process. This technology has significant applications across multiple sectors, including combustion, pollution treatment, medical, bio-electrics, automotive, defense, aerospace, heavy transport, energy, and agriculture. By enabling longer spark plug life and enhancing combustion efficiency, Transient Plasma Systems aims to drive technological advancements and improve operational effectiveness in these industries.

Stoicheia is a nanotechnology company accelerating materials discovery by defining and expanding the materials genome. Using its proprietary lithography technology, Stoicheia has developed a way to create Megalibraries of nanomaterials on a chip. The company's technology also can be used to combine elements in new ways — already creating structures comprising up to seven elements.

Siege Pharmaceuticals is focused on developing innovative cancer drugs that utilize synthetic variants of a naturally occurring molecule to effectively starve cancer cells. These drugs are designed with optimized properties to target multiple pathways essential for cancer cell growth, thereby inhibiting their development and resistance. By addressing these critical pathways, Siege Pharmaceuticals aims to provide medical practitioners with effective tools to control the proliferation of cancer cells and prevent further complications in treatment.

NVasc is an early-stage ophthalmology company with a focus on treating blindness. It specializes in treating the leading causes of blindness through choroidal and retinal revascularization. The company has acquired the research rights to growth factors (NVB001 and NVB002) that have been shown to encourage the growth of non-leaking new vessels in the retina and choroid in mouse models of ischemic eye diseases. The company is planning to manufacture NVB001 which can be used in toxicokinetic studies and in early clinical trials in humans.

Linnaeus Therapeutics, Inc. is a biotechnology company based in Haddonfield, New Jersey, focused on the identification and development of small molecule agents for the treatment of cancer and skin pigmentation disorders. Founded in 2016, the company builds on research from the Ridky lab at the University of Pennsylvania. Linnaeus's therapeutics are designed to modulate cellular differentiation, allowing for the precise regulation of melanin production in skin cells. This approach aims to provide effective treatments for conditions associated with oncogenic mutations, thereby addressing both cancer and disorders related to pigmentation.

LifeSprout is developing the next generation of synthetic soft tissue substitutes for aesthetic and reconstructive medicine. They offer revolutionary products for aesthetic and regenerative medicine. They have created a platform that looks and behaves like the body’s own tissues. The company is turning this into a suite of products for millions of patients each year with soft tissue losses from aging, cancer, and metabolic disease.

PolyCera, Inc. specializes in the development and manufacturing of advanced ultrafiltration membranes made from organic polymer materials. Founded in 2012 and based in Los Angeles, California, the company offers products such as the PolyCera hydro, a sub-20 nm membrane effective in removing bacteria, viruses, and protozoa, and the PolyCera titan, a sub-5 nm membrane known for its stability in challenging conditions including extreme pH, temperature, and fouling. These membranes feature a unique Spiral Monolith design that combines the advantages of polymeric, tubular, and ceramic membranes, resulting in high permeability and reduced operational costs. PolyCera membranes are oleophobic and hydrophilic, allowing for easy backwashing, which minimizes downtime and the need for cleaning chemicals. With a current installed capacity exceeding 55 million gallons per day, PolyCera membranes are utilized in various sectors, including clean energy, industrial wastewater management, and municipal water treatment. The company was acquired in 2020 by PSP.US, Inc., which continues to market its innovative filtration products under the PolyCera brand.

nFugue is building on the groundbreaking work developed at Caltech to open a new level of nano-architected materials that can be used for a wide variety of applications, from tiny medical implants to ultra-lightweight impact-resistant fabrics or textiles to ultra-lightweight aircraft components. The revolutionary process will reduce the size of the 3D printed structures by 5x while enabling a whole new set of unprecedented combinations of properties, for example, ultra-lightweight; thermally insulating; strong, stiff, and low-density; and impact-absorbing.

Tanvas, Inc. is a technology company based in Chicago, Illinois, focused on developing Surface Haptics products that enhance touch interactions on screens. Founded in 2011, Tanvas creates innovative touchscreen technology that utilizes electrostatic fields to generate variable friction on glass surfaces. This allows users to feel textures and sensations that correspond to visual content, transforming the way people interact with digital displays. By integrating their TanvasTouch technology into various touch-enabled products, the company caters to diverse industries, including automotive, retail, consumer electronics, and applications for the visually impaired. Tanvas aims to redefine the tactile experience, providing a richer and more immersive interaction with digital environments.

Keren Therapeutics is harnessing the biology of a naturally occurring peptide hormone to restore muscle function in the context of several musculoskeletal and muscle wasting diseases. Using the same biological insights, Keren is also developing a therapeutic to counteract cognitive decline associated with age-related neurodegenerative conditions.

DigitalGenius, Inc. is a company that specializes in developing artificial intelligence software solutions aimed at enhancing customer service operations, particularly in the E-commerce sector. Founded in 2013 and located in San Francisco, California, DigitalGenius offers a platform that utilizes advanced AI technologies, including conversational AI and visual recognition, to automate and optimize customer interactions across various channels. The platform effectively analyzes incoming messages, predicts metadata, routes inquiries, and provides agents with helpful suggestions, which helps automate responses and improves the quality of customer conversations. By integrating deeply with existing systems, DigitalGenius enables companies to scale their customer service operations, ensuring efficient and effective resolution of inquiries while meeting and exceeding customer expectations.

Provivi Inc. specializes in developing biopesticides aimed at pest management in agriculture, commercial sectors, households, and public health. The company's innovative approach focuses on using insect pheromones, which provide a safe, environmentally friendly alternative to traditional pesticides. By leveraging biocatalysis technology initially developed at the California Institute of Technology, Provivi enhances the synthesis of these biopesticides, ensuring they are effective and free from toxic residues. Founded in 2013 and based in Santa Monica, California, the company collaborates with distributors worldwide to deliver its products, which are designed to protect food supplies sustainably and affordably. With a team of experienced professionals from biotechnology and the agricultural chemicals industry, Provivi is positioned to transform pest management practices through its advanced biological processes.

1200 Pharma is a biopharmaceutical company focused on enhancing drug development processes through innovative technology. By integrating advanced medicinal chemistry from Caltech with proprietary biomarker-driven assays developed at UCLA, 1200 Pharma significantly reduces the time required for pre-clinical drug discovery and clinical approval. The company's platform utilizes UCLA's drug screening tools alongside Caltech's chemistry research to identify promising targets for clinical success. This approach enables researchers to create proprietary drugs with optimized profiles, ultimately aiming to streamline the pathway from discovery to market.

Symbiotix Biotherapies specializes in developing a novel class of molecular therapeutics aimed at treating inflammatory bowel disease (IBD), multiple sclerosis (MS), and other serious immune-mediated diseases. The company focuses on creating first-in-class oral agents derived from the human microbiome, which are designed to modulate T regulatory cells (Tregs). By leveraging these unique molecules, Symbiotix Biotherapies aims to provide patients with effective treatment options that enhance their quality of life and empower them to manage their conditions more effectively.

MixComm Inc. is a fabless semiconductor company based in Chatham, New Jersey, specializing in the development of wireless technology solutions for a variety of applications. Founded in 2017, the company focuses on creating advanced millimeter-wave products using RFSOI process technology. These products are designed to enhance performance and integration for 5G infrastructure and satellite communication. MixComm's offerings cater to numerous electronic devices, including smartphones, laptops, Wi-Fi routers, smart TVs, game consoles, virtual-reality headsets, and radar systems used in vehicles and defense electronics. By providing application-specific chips, MixComm aims to support the evolving needs of the wireless communications market.

Diabetic Retinopathy is the leading cause of vision loss in adults worldwide. Opera Therapeutics is developing treatments based on technology from Columbia University that harnesses a natural cellular mechanism to prevent the damage and cell death that are hallmarks of Diabetic Macular Edema (DME) and Retinal Vein Occlusion (RVO) which account for the majority of vision loss amongst people with diabetes. Unlike currently available anti-angiogenesis therapies which are injected directly into the eye, carry the risk of thromboembolic side effects, and are frequently ineffective, Opera Therapeutics is developing a biologic with a unique mechanism of acting for topical administration as an eye-drop, and aims to bring enhanced relief to patients suffering from diabetic retinopathy without the requirement for regular interocular injections. Opera Therapeutics is additionally exploring the utility of their biologics for treating stroke-induced edema in the brain.

Sienza Energy is focused on developing innovative rechargeable battery technology with a distinct approach to design and manufacturing. The company utilizes a 3D nanotechnology electrode structure, leveraging recent advancements across various fields to create high-density batteries. This unique method significantly enhances both energy and power densities while aiming to lower overall battery costs. Sienza Energy's technology offers increased capabilities for a variety of applications, ranging from smart devices to electric vehicles, positioning the company as a key player in the evolving battery industry.

Repairogen is a company focused on developing advanced anti-aging skincare products and ingredients that leverage proprietary DNA-repair technologies. Founded in 2012 and based in New York, the company’s offerings are designed to address DNA damage related to skin aging and related diseases. By utilizing a platform technology developed at a prestigious medical research institution, Repairogen aims to enhance skin health and appearance, significantly reducing DNA damage in skin cells, particularly after UV exposure. Their products not only contribute to healthier, younger-looking skin but also assist medical professionals in lowering the risk of skin cancer for patients.

GuRu Wireless, Inc. enables safe, effective and customizable transmission of power over-the-air using proprietary millimeter-wave (mmWave) integrated circuits, modules and proprietary Smart RF Lensing technology. A miniature-sized power transfer system delivers power at an unprecedented distance efficiently and with precision. GuRu's wireless solution can be used as a charging hub or a power source in many settings where access to an energy source is needed. It is easy to install, safe, and sophisticated enough to find and adjust for various power levels to sync with the needs of any device. Even during use, it continuously charges devices and as a safety measure, reroutes power as necessary. Founded in 2017 by a team of scientists and engineers from Caltech, GuRu aims to ensure access to power be as ubiquitous as WiFi.

Transient Plasma Systems, Inc. specializes in the development and manufacture of pulsed power systems for various research and commercial applications. Founded in 2009 and based in Torrance, California, the company produces pulse generators and nanosecond pulsed power systems that facilitate voltage and current measurement. Its innovative technology utilizes ultra-fast, high-voltage electrical pulses to create energetic electrons throughout a volume, rather than focusing them at a single point, which results in a more efficient ignition process. This technology has significant applications across multiple sectors, including combustion, pollution treatment, medical, bio-electrics, automotive, defense, aerospace, heavy transport, energy, and agriculture. By enabling longer spark plug life and enhancing combustion efficiency, Transient Plasma Systems aims to drive technological advancements and improve operational effectiveness in these industries.

Chimera Bioengineering focuses on developing gene therapeutics that aim to reprogram the immune system for cancer treatment. Their innovative approach utilizes chimeric antigen receptor T-cells (CARs), which are engineered immune cells designed to overcome immune evasion by targeting and eliminating tumor cells that express specific antigens. While existing CAR therapies have shown promise in treating liquid tumors such as acute lymphoblastic leukemia and lymphoma, challenges remain in addressing solid tumors, managing toxicities, and ensuring long-lasting effectiveness. Chimera Bioengineering addresses these limitations by incorporating drug-responsive gene regulators that enhance CAR functionality. This strategy aims to minimize adverse effects, improve therapeutic efficacy, and extend the persistence of CARs, ultimately striving for more effective and sustainable cures for cancer patients, particularly those who have not responded to traditional therapies.

DEARhealth, Inc. is a health technology company based in Beverly Hills, California, that specializes in developing a software-as-a-service (SaaS) healthcare management platform tailored for medical providers and health insurers. Founded in 2013, the company focuses on value-based healthcare solutions aimed at enhancing the health outcomes and experiences of chronically ill patients while simultaneously reducing associated costs. Utilizing advanced data analytics, DEARhealth's platform facilitates coordinated care pathways, streamlines provider workflows, and supports organizational decision-making. The technology is specifically designed for the management of complex and costly diseases, enabling healthcare professionals to optimize care and improve measurable patient outcomes.

NanoClear Technologies is a Los Angeles-based startup focusing on nanotechnology and energy solutions. The company leverages proprietary technology developed by its co-founder during tenure at JPL/NASA, alongside expertise from staff with backgrounds from prestigious institutions like Caltech, UC Berkeley, UCLA, and MIT. NanoClear's innovative process alters the wettability of surfaces, primarily targeting anti-fogging applications for consumer wearables and anti-frost solutions for various industrial uses. The technology has broad applicability across multiple sectors, including automobiles, aerospace, and solar panels, positioning NanoClear as a versatile player in the nanotechnology market.

Actinobac Biomed, Inc. is a biopharmaceutical company based in Kendall Park, New Jersey, established in 2009. The company focuses on developing therapeutics for various medical conditions, including blood cancers, autoimmune diseases, and HIV. Its primary product, Leukotoxin, is a bacterial toxin that specifically targets white blood cells, offering a targeted approach for treating hematologic malignancies such as leukemia and lymphoma. Additionally, research indicates that Leukotoxin may be effective against infectious diseases like HIV/AIDS and tuberculosis, as well as autoimmune conditions including rheumatoid arthritis, multiple sclerosis, and psoriasis. Actinobac Biomed is committed to advancing Leukotoxin as a protein therapeutic, while also exploring derived peptides for broader applications. The company is engaged in early-stage drug discovery in collaboration with Magellan BioScience, aiming to maintain a robust pipeline of innovative therapeutic agents.

3D Bio Holdings is a biotechnology company specializing in bioprinting technologies to create patient-specific living tissues for surgical healing. Founded in 2014, the company is headquartered in Brooklyn, New York, with an additional office in New York City. Utilizing proprietary technologies such as GMPrint and ColVivo, 3D Bio Holdings aims to address the limitations of the body's natural healing processes by providing therapeutic solutions for various diseases and congenital medical conditions.

Holoclara is an immunotherapy company focused on developing treatments for autoimmune disorders using nematode-derived molecules. The company aims to provide relief to individuals suffering from these conditions by offering a range of services that include the delivery of therapeutics derived from worm species. These molecules are identified for their potent therapeutic properties and are being developed into safe, orally available treatments. Holoclara’s initiatives are designed to enable patients to lead healthier lives while addressing the challenges posed by autoimmune disorders.

Neuro-Bio is a start-up dedicated to creating innovative therapeutics for neurodegenerative disorders such as Alzheimer’s, Parkinson’s, and Motor Neuron Disease. The company distinguishes itself through its focus on identifying the initial triggers of neurodegeneration, a concept developed by Baroness Professor Susan Greenfield during her extensive 40-year career in neuroscience. Neuro-Bio is engaged in the discovery and development of oral medications and a biomarker for identifying novel amino acid bioactive peptides. This approach aims to provide physicians with effective treatment options for neurodegenerative and related diseases.

Amorphology is a manufacturer specializing in the development of specialty metallic parts through innovative metal alloy technologies. The company focuses on producing lightweight, precision gearboxes designed specifically for non-commercial robotics applications. By utilizing advanced production techniques, Amorphology aims to enhance the performance, durability, elasticity, and wear resistance of machinery used in various industries. Their expertise in metal production and material innovation positions them to meet the growing demands of collaborative robotic systems and other lightweight operational needs.

Behavioral Signals specializes in technology that analyzes human behavior through voice data, focusing on emotion recognition and behavioral analytics. Their primary product, AI-MC, allows enterprises to enhance call center performance by automatically matching customers with the most suitable agents based on voice data and emotional insights. The company utilizes proprietary algorithms to identify core emotions, moods, and interaction patterns, translating these factors into key performance indicators for marketing campaigns. By processing data in real-time, Behavioral Signals enables clients to gain valuable emotional and demographic insights, which can be integrated into various applications and processes to improve overall business outcomes.

Axial Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapeutics for central nervous system diseases and disorders. Based in Waltham, Massachusetts, the company utilizes a microbiome discovery platform that targets the gut-brain axis, allowing for the exploration and creation of innovative therapies aimed at improving the quality of life for patients suffering from neurological conditions. Incorporated in 2013, Axial Biotherapeutics seeks to advance its pipeline of novel treatments to address the unmet needs in the field of CNS disorders.

Axial Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapeutics for central nervous system diseases and disorders. Based in Waltham, Massachusetts, the company utilizes a microbiome discovery platform that targets the gut-brain axis, allowing for the exploration and creation of innovative therapies aimed at improving the quality of life for patients suffering from neurological conditions. Incorporated in 2013, Axial Biotherapeutics seeks to advance its pipeline of novel treatments to address the unmet needs in the field of CNS disorders.

Gene Sciences, Inc. is a biotechnology company based in San Diego, California, established in 2016. The company focuses on developing innovative DNA-targeted therapeutics aimed at modulating gene expression for the treatment of various human diseases. Serving customers primarily in the United States, Gene Sciences is dedicated to advancing healthcare solutions through its research and development efforts in the biopharmaceutical sector.

MemiRay, LLC, founded in 2016 and based in Arcadia, California, specializes in the development of personal health monitoring devices. The company's flagship product, InstaPath, is designed to measure multiple human fluid analytics simultaneously, targeting conditions such as Diabetes Mellitus and Coronary Heart Disease while also monitoring hydration levels. In addition to its hardware, MemiRay offers cloud-based informatics software that ensures data integrity, security, and precise time stamping, facilitating effective record keeping and methodology management. The company's products are aimed at a wide range of users, including individuals and various healthcare facilities such as hospitals, surgery centers, and pathology labs. MemiRay's innovative approach emphasizes convenience, portability, and ease of use, contributing to improved health outcomes and reduced overall healthcare costs.

Applaud Medical, Inc. is a medical device company based in San Francisco, California, focused on developing and commercializing innovative treatments for kidney stones, a condition affecting over 2 million individuals annually in the United States. Established in 2014, the company aims to address the limitations of current treatment options, which often require anesthesia and operating room procedures for large stones. The existing least invasive surgical interventions achieve only a 50% stone-free rate. Applaud Medical's breakthrough approach will enable urologists to effectively treat 5-15 millimeter kidney stones through a simple outpatient procedure, significantly improving patient outcomes and convenience.

Compellon, Inc. is a data analytics software company based in Laguna Hills, California, founded in 2010. It specializes in providing prescriptive analytics solutions to various industries, including healthcare, financial services, and advertising. Compellon’s flagship products include Iris Pro, an analytics advisory tool; Compellon 20|20, a clear-box analytics platform; and 20|20 Survey, which focuses on survey analytics. The company leverages advanced artificial intelligence techniques to deliver actionable insights rapidly, enabling businesses to make informed decisions without requiring extensive technical expertise. By automating the analytics process, Compellon empowers organizations to optimize outcomes and address complex data challenges efficiently. Its technology functions as an autonomous intelligent agent that tailors analytics based on user-defined goals, allowing both data scientists and business analysts to uncover valuable insights from diverse data sets.

Delpor, Inc. is engaged in the development of innovative drug delivery technologies that facilitate the sustained or pattern-specific release of proteins, peptides, and small molecules via a small non-mechanical subcutaneous implant. The company offers several technologies, including Prozor, which delivers antipsychotics and other small molecule drugs, and NANOPOR, designed for sustained release through specialized membrane architecture. Additionally, Delpor has developed the Delos PUMP, a self-contained device that allows for the pulsed delivery of medications at programmed intervals, benefiting treatments such as hormones for fertility, diabetes management, and pain relief. Founded in 2009 and located in San Francisco, California, Delpor aims to enhance medication adherence and patient convenience by providing an alternative to frequent injections through its implantable solutions.

Provivi Inc. specializes in developing biopesticides aimed at pest management in agriculture, commercial sectors, households, and public health. The company's innovative approach focuses on using insect pheromones, which provide a safe, environmentally friendly alternative to traditional pesticides. By leveraging biocatalysis technology initially developed at the California Institute of Technology, Provivi enhances the synthesis of these biopesticides, ensuring they are effective and free from toxic residues. Founded in 2013 and based in Santa Monica, California, the company collaborates with distributors worldwide to deliver its products, which are designed to protect food supplies sustainably and affordably. With a team of experienced professionals from biotechnology and the agricultural chemicals industry, Provivi is positioned to transform pest management practices through its advanced biological processes.

Vivodyne specializes in developing an automated robotic platform that aims to advance drug discovery and cellular therapies. The company's innovative microfluidic bioengineering technology facilitates the culture of highly realistic human tissue models, allowing researchers to explore complex biological processes. By employing single-cell 4D phenomics and integrating advanced imaging techniques, Vivodyne's system enables the formulation of tailored mixtures of compounds and cell therapies. This comprehensive approach not only accelerates the development of potential cures for various human diseases but also enhances the understanding of human health at a cellular level.